Fool dismayed by pharma; UPS names biotech expert to board;

> David Williamson of the Motley Fool asks, "What happened?" after reviewing recent Big Pharma earnings. Story

> Logistics giant UPS has upped its commitment to the biopharma industry by naming its 12th director, Candace Kendle, former chairman and co-founder of contract researcher Kendle International. UPS release

> Visiongain projects global contract manufacturing revenues will experience nearly 9% annual growth through 2016, for a $64 billion market. Visiongain release

> If the future of drugs is biotech, then syringe-making is a good place to be. Unilife release

> Credit Mylan boss Heather Bresch for consistently pushing an agenda of foreign pharma plant inspections by the FDA. Story

> U.S. Customs and Border Protection seized a package containing more than 8,000 counterfeit erectile dysfunction pills at a DHL facility at the Cincinnati/Northern Kentucky International Airport. News

> Conduct plant security vulnerability assessments annually; create layers of security and put the most critical assets in the most inner layer. Article

> Jubilant Life Sciences in India has signed a three-year, $80 million supply agreement with an unnamed life sciences company to integrate "an in-house developed technology" with captively produced raw material. Announcement

> Ghanian drug officials say they will investigate whether drug barons are sponsoring the production of the fake antibiotics and condoms circulating in the West African country. Story

> On average, the National Health System in Spain takes 410 days to pay manufacturers for the drugs used in hospitals. Article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.